Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery

Abstract

DendGDP is sensitive to cathepsin B in tumor cells and can be used as a cathepsin B-responsive drug targeting strategy. We suggest that DendGDP is a promising vehicle for cancer cell targeting.